BioLife Solutions director disposes of 57,995 shares

BioLife Solutions director Rachel Ellingson sold 57,995 shares on October 6, 2026, as part of a merger with Repligen. Each share was converted to $11.25 in cash and 0.1442 Repligen shares, per the merger agreement. Ellingson held no shares post-transaction.

Original reporting
Published Oct 9, 2026, 1:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 8:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$BLFS
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

Low
01

Why it matters

The insider sale is a routine post‑merger transaction with limited market impact.

02

Market read

Small insider sale after merger; unlikely to move the stock significantly.

03

What to watch

Potential tax or liquidity reasons for the sale that do not reflect company fundamentals.

Relevance 4/10Novelty 4/10Timing: post‑merger disclosure on Oct 6 2026

Background

BioLife Solutions completed its merger with Repligen, converting each share into cash and Repligen stock. The filing reports the director's share disposition.

Market effects

Minimal; the biotech merger has already been priced in.

None; the filing is company‑specific.

None

Counterpoint

The insider sale could be interpreted as a lack of confidence in post‑merger integration.

Key entities

  • BioLife Solutions Inc.

    Biotech firm completing merger with Repligen.

  • Rachel Ellingson

    Director of BioLife Solutions who sold her shares.

Related articles

$RGENHighAI 8/10

REPLIGEN CORP (RGEN): Completion of Acquisition or Disposition of Assets

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONS WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company foc

$RGENHigh

BIOLIFE SOLUTIONS INC (BLFS): Completion of Acquisition or Disposition of Assets

BIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. At the effective time of the First Merger (the “First Merger Effective Time”), ea

$RGENHighAI 8/10

Repligen Completes Acquisition of BioLife Solutions

Repligen Corporation (NASDAQ: RGEN) completed its acquisition of BioLife Solutions (NASDAQ: BLFS) for $11.25 per share in cash and 0.1442 shares of Repligen stock. The deal expands Repligen's presence in the cell therapy market, adding high-margin consumables and recurring revenue. BioLife's products support 18 approved therapies and most U.S. cell-based therapy trials. Repligen will discuss the transaction's financial impact on its Q3 2026 earnings call.

$FRSHHighAI 8/10

Freshworks to Replace BioLife Solutions in S&P SmallCap 600

S&P Dow Jones Indices announced Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 on October 8, 2026. Repligen (RGN) is acquiring BioLife for $1.5B, with BioLife shareholders receiving $11.25 per share in cash and 0.1442 shares of Repligen stock. Freshworks reported Q2 2026 revenue of $237.4M, up 16% YoY, and its first GAAP profitability in 2026.